A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.

Inclusion Criteria

* Subject must be \>/= 18 years of age.
* Subject must have a histologically or cytologically confirmed non-hematologic malignancy.
* Eastern cooperative Oncology Group (ECOG) Performance Score of 0 to 2.
* Subject must have adequate bone marrow, renal and hepatic function.
* Subject must have Partial Thromboplastin Time (PTT) \</= 1.5 x Upper Limit of Normal (ULN) and International Normalized Ratio (INR) \</= 1.5.
* Subject must be capable of understanding and complying with parameters as outlined in the protocol and able to sign the informed consent.

Exclusion Criteria

* Subject has received previous administration of a radiolabeled research substance within 12 months prior to Study Day 1 or exposure to significant radiation (e.g., barium meal, etc.) within the past 3 months or within a period defined by 5 half-lives, whichever is shorter, prior to Study Day 1.
* Subject has received anti-cancer therapy including investigational agents, cytotoxic chemotherapy, radiation, hormonal or biologic therapy within 21 days or within a period defined by 5 half-lives, whichever is shorter, prior to Study Day 1.
* Subject is currently using a known inhibitor (e.g., ketoconazole) or inducer (e.g., rifampin) of cytochrome P450 3A (CYP3A) within 1 month prior to Study Day 1.
* Subject has not recovered to less than or equal to grade 1 clinically significant adverse effects/toxicities of the previous therapy.
* Subject has undergone major surgery within 21 days of Study Day 1.
* The subject has brain or meningeal metastases.
* The subject has non-small cell lung cancer (NSCLC) with a predominant squamous cell histology.
* Subject is receiving therapeutic anticoagulation therapy.
* Subject has a history of/or currently exhibits clinically significant events of bleeding (e.g., hemoptysis).
* Subject has proteinuria Common Terminology Criteria (CTC) Grade \> 2 at baseline.
* Subject currently exhibits symptomatic or persistent, uncontrolled hypertension.
* Subject has a history of myocardial infarction within 6 months.
* Subject has known autoimmune disease with renal involvement.
* Subject is receiving combination anti-retroviral therapy for human immunodeficiency virus (HIV).
* Clinically significant uncontrolled conditions/medical symptoms.
* Subject has a documented left ventricular (LV) ejection fraction \< 50%.
* Subject has previously received linifanib.